Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs
- 7 July 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (1), 25-30
- https://doi.org/10.1161/01.cir.98.1.25
Abstract
Background—The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction. We compared the coronary vasoconstrictor potential...Keywords
This publication has 38 references indexed in Scilit:
- Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonistBritish Journal of Clinical Pharmacology, 1997
- 5‐HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5‐HT and sumatriptan with rizatriptan and L‐741,519British Journal of Clinical Pharmacology, 1996
- Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT1Dreceptor agonistsExpert Opinion on Investigational Drugs, 1996
- The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteersBritish Journal of Clinical Pharmacology, 1996
- A comparison of the contractile effects of 5‐hydroxytryptamine, sumatriptan and MK‐462 on human coronary artery in vitro.British Journal of Clinical Pharmacology, 1995
- Sumatriptan Clinical PharmacokineticsClinical Pharmacokinetics, 1994
- SumatriptanDrugs, 1994
- Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature ReviewHeadache: The Journal of Head and Face Pain, 1991
- Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster HeadacheClinical Pharmacokinetics, 1985
- Effects of 5-Hydroxytryptamine and Ergotamine on Human Superficial Temporal ArteryCephalalgia, 1981